Acura Pharmaceuticals announces financial results
PALATINE -- Acura Pharmaceuticals Inc. reported a net loss of $1.2 million, or 4 cents per diluted share, for its fiscal year ended Dec. 31, compared to a net loss of $3.8 million, or 14 cents per diluted share, for the same period in 2019.
For the year, the company recorded $3 million in license fees, $200,000 in collaboration revenue and $100,000 million in royalty revenue. Both the license fee revenue and the collaboration revenue are derived from a license agreement with Abuse Deterrent Pharma executed in 2019.
Research and development expense was $1.8 million in 2020, compared to $1.5 million in 2019, the company said.
Acura Pharmaceuticals is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications.